Sanofi-Aventis
Company and Pharmaceutical Company
Living Without Blockbusters...assembling a committee of experts on diabetes and tumors to refute the connection. Viehbacher's assignment to Sanofi initially seemed like a booby prize. He had just lost a contest to run his previous employer, number two drugmaker... In this article: Sanofi, Bristol-Myers Squibb, Pfizer, Cancer, Breast cancer, Sanofi-Synthelabo, Novartis, and Glaxo |
-
Seeking Alpha | 5 days ago
Oral-lyn vs. Afresa: How Generex Will Beat Mannkind
...testing and Phase IV monitoring. Also in June, the FDA said it is reviewing data on the safety of Sanofi-Aventis's (SNY) popular Lantus insulin over highly publicized and inconsistent cancer findings. There has only been one new diabetes...
In this article: Insulin, FDA, Glucose, Novo Nordisk, Phase IV, and Hyperglycemia
-
Miami Herald - Breaking News | October 30, 2009
Exelixis shares rise on 3Q results
...of $46.6 million. Exelixis said the revenue boost came from new partnerships with Sanofi-Aventis and Bristol-Myers Squibb on potential cancer treatments and Boehringer Ingelheim on autoimmune disease treatments. The Miami Herald is...
In this article: Revenue, Cancer, Autoimmune disease, Thomson Reuters, Bristol-Myers Squibb, Boehringer Ingelheim, The Miami Herald, and South San Francisco, Calif.
-
Sanofi-Aventis to Establish Venture Capital Fund, Looking for 'Right Brain Activity'
...a partnership deal with Merrimack Pharmaceuticals focused on the biotech's experimental antibody drug for cancer, and continues Sanofi's strategy of looking outside the company for what Viehbacher calls "right brain activity" that leads...
In this article: Regeneron, Venture capital, Venture Capital Fund, United States, Revenue, Time horizon, and Cancer
-
New Kerala | October 29, 2009
Sanofi signs agreement with Micromet for 'Bite' anibody development
-
Xconomy | November 10, 2009
Right Brains Wanted: Sanofi-Aventis Wants to Tap the Creative Genius of Boston-Area Biotechs
...of the company. Sanofi, like many other Big Pharma companies, is looking outside of its organization to biotech firms for what Viehbacher called the "right brain activity" that leads to creativity and innovation. Sanofi's shift toward...
In this article: Boston, Clopidogrel, Zolpidem, Cambridge, MA, Venture capital, and Cancer
-
Philly.com | September 14, 2009
Appeals court reverses approval for Teva, others
...for Teva, others A federal appeals court has reversed a decision giving Teva Pharmaceutical Industries Ltd. and other drug-makers the right to make a generic form of a Sanofi-Aventis drug to treat stage 3 colon cancer. The appeals court...
In this article: U.S., Legal age, Sanofi pasteur, Eloxatin, Cancer, Teva Pharmaceutical Industries Ltd., and U.S. Food and Drug Administration
-
Cramer's Mad Money - The Best Thing That Ever Happened to Lear (11/20/09)
...bearish news next week. CEO Interview: CEO Chris Viehbacher, Sanofi-Aventis (SNY) Sanofi-Aventis (SNY) CEO Chris Viehbacher admits his company has "a big patent-expiration problem;" 41% of the pharmaceutical company's 2009 sales are...
In this article: Jim Cramer, Lear, J.Crew, Bankruptcy, FRO, Magna International, Gentex, and Hewlett Packard
Trends
Loading...
More on Sanofi-Aventis
Description from Wikipedia:
Sanofi-Aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world's fourth-largest by prescription sales. Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur). The company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
- Name:
- Sanofi-Aventis S.A.
- Type:
- Public (Euronext: SAN, NYSE: SNY, LSE: 0I42, FWB: SNW)
- Location:
- Paris, France
- Founded:
- 20 August 2004 (by acquisition)
- Stock Symbol:
- SNY
- Industry:
- Pharmaceuticals
- Key People:
- Chris Viehbacher , Jean-François Dehecq
- Products:
- Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
- Revenue:
- €27.57 billion
- Operating Income:
- €4.394 billion
- Net Income:
- €3.851 billion
- No. of Employees:
- 98,210
- Subsidiaries:
- Sanofi Pasteur
Explore everything named Sanofi-Aventis...
